Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 11Radiotherapy 6Lomustine 3Vincristine 2Procarbazine 2Carmustine 2veliparib 1trametinib 1selinexor 1ribociclib 1lonafarnib 1dabrafenib 1carmustine, poliferprosan 20 drug combination 1Watchful Waiting 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Psychiatric Rehabilitation 1Platelet Count 1Panobinostat 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Hydroxychloroquine 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Glioma × veliparib × Clear all
NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Radiation Therapy Oncology Group

Phase 1/2 Completed
257 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡